Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. conventional anthracycline-containing regimens. Both taxanes are Docetaxel as Neoadjuvant Therapy in Early- now recommended for standard preoperative systemic treatment in Stage or Locally Advanced Breast Cancer many countries, because the above-mentioned aims can be effec- A Viewpoint by Gunter von Minckwitz tively achieved, despite an increase in toxicity. However, the German Breast Group, GBG Forschungs GmbH, question of whether sequential or simultaneous application of the Neu-Isenburg, Germany anthracycline and the taxane is superior remains unresolved. Moreover, the impact of treatment duration, which is usually Primary breast cancer is considered today as a systemic disease longer for sequential regimens, is unknown in the neoadjuvant with a locoregional component. Systemic treatment is, therefore, setting. considered a fundamental component of the medical management of patients suffering from this endemic malignancy. Postoperative The neoadjuvant approach is scientifically considered to be an applications of chemo-, endocrine, or immunologic therapies are in vivo chemosensitivity test. Prediction of response by early always lacking the control of efficacy in the short term. Converse- physical or sonographic response evaluation, as well as by tissue ly, preoperative treatment allows the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

American Journal of Cancer , Volume 5 (3) – Aug 10, 2012

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. conventional anthracycline-containing regimens. Both taxanes are Docetaxel as Neoadjuvant Therapy in Early- now recommended for standard preoperative systemic treatment in Stage or Locally Advanced Breast Cancer many countries, because the above-mentioned aims can be effec- A Viewpoint by Gunter von Minckwitz tively achieved, despite an increase in...
Loading next page...
 
/lp/springer-journals/docetaxel-as-neoadjuvant-therapy-in-early-stage-or-locally-advanced-c1FIfGjnDF
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605030-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. conventional anthracycline-containing regimens. Both taxanes are Docetaxel as Neoadjuvant Therapy in Early- now recommended for standard preoperative systemic treatment in Stage or Locally Advanced Breast Cancer many countries, because the above-mentioned aims can be effec- A Viewpoint by Gunter von Minckwitz tively achieved, despite an increase in toxicity. However, the German Breast Group, GBG Forschungs GmbH, question of whether sequential or simultaneous application of the Neu-Isenburg, Germany anthracycline and the taxane is superior remains unresolved. Moreover, the impact of treatment duration, which is usually Primary breast cancer is considered today as a systemic disease longer for sequential regimens, is unknown in the neoadjuvant with a locoregional component. Systemic treatment is, therefore, setting. considered a fundamental component of the medical management of patients suffering from this endemic malignancy. Postoperative The neoadjuvant approach is scientifically considered to be an applications of chemo-, endocrine, or immunologic therapies are in vivo chemosensitivity test. Prediction of response by early always lacking the control of efficacy in the short term. Converse- physical or sonographic response evaluation, as well as by tissue ly, preoperative treatment allows the

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References